Deal Details
Allogene Completes $200.4 Million Follow-On Offering
Summary
Allogene Therapeutics, Inc. (“Allogene”) (NASDAQ: ALLO) recently completed the pricing of an underwritten public offering (the “Offering”) of 100,200,000 shares of its common stock, including 12,700,000 shares sold pursuant to the partial exercise of the underwriters’ option to purchase additional shares, at a price of $2.00 per share, generating gross proceeds of approximately $200.4 million. Allogene expects to use the net proceeds from this Offering for general corporate purposes, which may include clinical trial expenses, research and development expenses, general and administrative expenses and capital expenditures.
Baird served as a lead manager on this Offering.
About
Allogene is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer and autoimmune disease. Led by cell therapy veterans applying proven CAR T experience, Allogene is developing a pipeline of off-the-shelf CAR T cell product candidates with the goal of delivering readily available cell therapy on-demand, more reliably and at greater scale to more patients. Allogene is headquartered in South San Francisco, California.CONTACT US TO LEARN MORE
- Date
- April 2026
- Company
- Allogene Therapeutics, Inc.
- Transaction
- Equity Capital Markets
- Sectors
- Healthcare
- Verticals
-
Biotechnology & Pharmaceuticals
- Target Geography
- North America
Share
